Fig. 6: Eliglustat synergizes with ICB.

a Experimental design. C57BL/6 mice were transplanted with 1 × 10⁵ MC38-OVA cells and treated with PBS (CON group), eliglustat alone (ELI, 10 mg/kg), an anti-PD-1 antibody alone (a-PD-1, 200 mg/kg per mouse) or eliglustat plus anti-PD-1 as indicated (ELI+ a-PD-1). Tumour sizes were examined every other day. b Average and individual tumour growth curves of each treatment group are shown (n = 7). c The phenotype and function of tumour-infiltrating lymphocytes from MC38-OVA tumours were determined by flow cytometry analysis on Day 21 after tumour inoculation (n = 3). CD4⁺ T cells, CD8⁺ T cells, IFN-γ, TNF-α, PD-1, TIM-3 and tetramer⁺ cell surface levels in the tumours of different treatment groups. Absolute numbers of CD4⁺ T cells, CD8⁺ T cells and IFN-γ⁺, TNF-α⁺, and tetramer⁺ T cells per 10⁶ cells (n = 3). Bar colours (d): control (red), eliglustat (cyan), ant-PD-1 (dark green), eliglustat + anti-PD-1 (orange). The data represent three independent experiments with similar results. The data are presented as the means ± SEMs. ns, not significant. P values were determined by two-way repeated measures ANOVA in (b) and unpaired two-sided t tests in (c). CON control, ELI eliglustst. Source data and exact p values are provided as a Source Data file.